Pulmonary complications in chronic lymphocytic leukemia

Although pulmonary complications account for significant morbidity and mortality in patients with chronic lymphocytic leukemia (CLL), to the authors' knowledge there are sparse data available in published literature. The authors evaluated pulmonary complications in patients with CLL and identified prognostic variables that predict hospital mortality in these patients.

[1]  M. Szathmári,et al.  Immunologic and molecular biologic characterization of pleural involvement in a case of T-chronic lymphocytic leukemia. , 1994, Chest.

[2]  M. Keating,et al.  Infection and immunity in chronic lymphocytic leukemia. , 2000, Mayo Clinic proceedings.

[3]  S. Swerdlow,et al.  Pleural involvement in B-cell chronic lymphocytic leukemia associated with a T-cell-rich "reactive" pleural effusion. , 1986, The American review of respiratory disease.

[4]  M. Baer,et al.  Chronic lymphocytic leukemia with hyperleukocytosis the hyperviscosity syndrome , 1985, Cancer.

[5]  M. Fisch,et al.  Predicting death in patients hospitalized for community-acquired pneumonia. , 1991, Annals of internal medicine.

[6]  K. Rai,et al.  Prognostic factors and clinical staging in chronic lymphocytic leukemia. , 1990, Hematology/oncology clinics of North America.

[7]  J. Rowe,et al.  Hyperleukocytic Leukemias: Rheological, Clinical, and Therapeutic Considerations , 1982 .

[8]  W. C. Ball,et al.  Pleural effusions: the diagnostic separation of transudates and exudates. , 1972, Annals of internal medicine.

[9]  M. Kris,et al.  The clinical course of lung carcinoma in patients with chronic lymphocytic leukemia , 1999, Cancer.

[10]  L. Snyder,et al.  Endobronchial Richter's syndrome. A rare manifestation of chronic lymphocytic leukemia. , 1988, The American review of respiratory disease.

[11]  M. Greene,et al.  Solid tumors after chronic lymphocytic leukemia. , 2001, Blood.

[12]  J. Byrd,et al.  Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes. , 2002, Chest.

[13]  A. Polliack,et al.  Pulmonary involvement as the major manifestation of chronic lymphocytic leukemia. , 1992, Leukemia & lymphoma.

[14]  R. Larson,et al.  Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Kantarjian,et al.  Richter's syndrome: a report on 39 patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. Rosenow,et al.  Pulmonary Disease in the Immunocompromised Host (First of Two Parts) , 1985 .

[17]  B. Hankey,et al.  Second cancers in patients with chronic lymphocytic leukemia. , 1992, Journal of the National Cancer Institute.

[18]  E. Henderson,et al.  An autopsy study of 1206 acute and chronic leukemias (1958 to 1982) , 1987, Cancer.

[19]  A. Dear,et al.  Pulmonary chronic lymphocytic leukemia: Difficulty in establishing a tissue diagnosis , 1995, European Journal of Haematology.

[20]  C. Wanke,et al.  Single-agent/combination therapy of human immunodeficiency virus-related wasting. , 1998, Seminars in oncology.

[21]  A. Marchevsky,et al.  Computerized interactive morphometry. An expert system for the diagnosis of lymphoid-rich effusions. , 1989, American journal of clinical pathology.

[22]  T. Colby,et al.  Bronchiolocentric chronic lymphocytic leukemia , 1986, Cancer.

[23]  J. W. Johnson,et al.  Pulmonary leukostasis as the single worst prognostic factor in patients with acute myelocytic leukemia and hyperleukocytosis. , 1985, The American journal of medicine.

[24]  N. Schluger,et al.  Pulmonary Disease in the Immunocompromised Host , 2001 .